Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Tammie Holcomb

Nurse Practitioner, Gerontology Camden, TN Nurse Practitioner

NPI 1114369998 CMS profile 11150020

190 W Main St, Camden, TN 38320

Open in the dashboard

General payments

$1,158

53 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tammie Holcomb of Camden, TN is reported in the CMS Open Payments database as having received $1,158 across 53 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $359 13
2024 General $302 17
2023 General $400 18
2022 General $98 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tammie Holcomb
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Tammie Holcomb were reported at $359. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Tammie Holcomb Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $133 $44–$396 $132
2022 $98 $142 $48–$452 $149
2023 $400 $158 $53–$482 $160
2024 $302 $171 $55–$533 $164
2025 $359 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Amgen Inc. $237 14 payments
  2. Novo Nordisk Inc $187 4 payments
  3. AbbVie, Inc. $133 7 payments
  4. AstraZeneca Pharmaceuticals LP $120 6 payments
  5. Astellas Pharma US Inc $100 1 payment
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $76 5 payments
  7. Pfizer Inc. $63 3 payments
  8. Otsuka America Pharmaceutical, Inc. $45 2 payments
  9. Dexcom, Inc. $43 2 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $37 2 payments
  11. Other $119 7 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $1,058 52 payments
  2. Education $100 1 payment
Products named General payments · program years 2022–2025
  1. Otezla $237 14 payments
  2. Repatha $223 13 payments
  3. Wegovy $171 3 payments
  4. AIRSUPRA $81 4 payments
  5. XIFAXAN $76 5 payments
  6. QULIPTA $69 3 payments
  7. VRAYLAR $64 4 payments
  8. NURTEC ODT $63 3 payments
  9. ZAVZPRET $45 2 payments
  10. REXULTI $45 2 payments
  11. Other $324 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 118 drugs

Part D claims

4,764

Median for Nurse Practitioner: 389

Drug cost

$384,863

Median for Nurse Practitioner: $21,885

Branded share of claims

20.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 67 $61,025
Trulicity Dulaglutide Brand 52 $47,811
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 47 $38,248
Ozempic Semaglutide Brand 39 $36,437
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 28 $25,130
Budesonide Er Budesonide Brand 11 $24,547
Januvia Sitagliptin Phosphate Brand 16 $21,400
Eliquis Apixaban Brand 26 $20,569
Mounjaro Tirzepatide Brand 15 $14,336
Repatha Sureclick Evolocumab Brand 20 $11,196

The 10 drugs with the highest cost, of 118 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Otezla
  • Amgen Inc. $40
$40 — —
Repatha
  • Amgen Inc. $40
$40 20 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $37
$37 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $37
$37 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $24
$24 47 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

53 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record